ABVC BioPharma CEO Uttam Patil decides to forgo salary

ABVC BioPharma announced the new CEO of ABVC has chosen to forgo a salary, instead opting for stock options as a pivotal component of his compensation package. ABVC’s current pipeline includes a completed Phase II study for a product aimed at major depressive disorder and discussions with the FDA regarding moving forward with the Phase III study. We are also advancing on a Phase IIb study in Attention Deficit Hyperactivity Disorder, ongoing at the University of California at San Francisco and the additional five sites in Taiwan. ABVC plans to accomplish these two tasks by the end of 2023. An evaluation is underway regarding reinstating the Vitargus trials and proceeding with the pivotal trials worldwide. Furthermore, BLEX 404, an oncology product for treating Non-Small Cell Lung Cancer and other cancer types based on combination therapy, has passed the IND approvals from US FDA and is in review at the Taiwan FDA to kick-start the trials.